论文部分内容阅读
目的探讨比较奥沙利铂联合替吉奥或紫杉醇脂质体化疗方案一线治疗晚期胃癌的疗效。方法选取2012年12月至2014年12月间广东省珠海市人民医院收治的96例晚期胃癌患者,均无法接受手术治疗,按照随机数字表法分为观察组和对照组,每组48例。观察组患者采用奥沙利铂联合替吉奥化疗方案,对照组患者采用奥沙利铂联合紫杉醇脂质体化疗方案。比较两组患者的疗效和不良反应。结果观察组患者的有效率和疾病控制率分别为41.7%和72.9%,对照组则分别为45.8%和70.8%,组间差异均无统计学意义(均P>0.05)。观察组患者疾病进展时间和生存时间分别为(5.3±0.6)个月和(12.3±0.8)个月,对照组则分别为(5.1±0.4)个月和(10.4±0.6)个月,组间疾病进展时间差异无统计学意义(P>0.05),生存时间差异有统计学意义(P<0.05);观察组患者关节肌肉疼痛和中性粒白细胞减少症发生率均低于对照组(均P<0.05)。结论奥沙利铂联合替吉奥治疗晚期胃癌患者,其生存情况和耐受性方面优于奥沙利铂联合紫杉醇脂质体方案,值得临床推广。
Objective To investigate the efficacy of oxaliplatin in combination with tegaserod or paclitaxel liposomal chemotherapy for first-line treatment of advanced gastric cancer. Methods A total of 96 patients with advanced gastric cancer who were admitted to Zhuhai People’s Hospital of Guangdong Province between December 2012 and December 2014 were not treated by surgery. According to the random number table, they were divided into observation group and control group, 48 cases in each group. Patients in the observation group were treated with oxaliplatin combined with tirofiban, and patients in the control group were treated with oxaliplatin combined with paclitaxel liposomal chemotherapy. The efficacy and adverse reactions of the two groups were compared. Results The effective rate and disease control rate in the observation group were 41.7% and 72.9% respectively, while those in the control group were 45.8% and 70.8% respectively. There was no significant difference between the two groups (all P> 0.05). The disease progression time and survival time were (5.3 ± 0.6) months and (12.3 ± 0.8) months in the observation group and (5.1 ± 0.4) months and (10.4 ± 0.6) months in the control group, respectively There was no significant difference in disease progression time between the two groups (P> 0.05), and the difference of survival time was statistically significant (P <0.05). The incidence of joint pain and neutropenia in the observation group was lower than that in the control group <0.05). Conclusion The combination of oxaliplatin and tioguanide in the treatment of patients with advanced gastric cancer is superior to oxaliplatin combined with paclitaxel liposome in survival and tolerability and is worthy of clinical promotion.